Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (onset® 3)
Sponsor: Novo Nordisk A/S
Listed as NCT01850615, this PHASE3 trial focuses on Diabetes and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 12 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Feb 2019 — Jul 2019 [monthly]
Completed PHASE3
-
Aug 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Apr 2017 — Feb 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .